NATCO Pharma Limited (BOM:524816)

Market Cap	175.29B +18.9%
Revenue (ttm)	45.63B +6.6%
Net Income	15.57B -16.5%
EPS	86.94 -16.5%
Shares Out	n/a
PE Ratio	11.26
Forward PE	20.11
Dividend	5.00 (0.51%)
Ex-Dividend Date	Feb 18, 2026

Volume	85,649
Average Volume	91,770
Open	961.35
Previous Close	973.75
Day's Range	954.55 - 981.00
52-Week Range	660.05 - 1,059.60
Beta	n/a
RSI	55.26
Earnings Date	May 26, 2026

About NATCO Pharma

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 4,199
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524816

Financial Performance

In fiscal year 2025, NATCO Pharma's revenue was 44.32 billion, an increase of 10.74% compared to the previous year's 40.02 billion. Earnings were 18.85 billion, an increase of 35.81%.